الفقاع الشرواني الفقاعي المعمم غير المستجيب على الرغم من العلاج المكثف المشترك بالكورتيكوستيرويدات الموضعية والجهازية

References

• In the cases of those few patients with generalized disease who remain below the controllable level (unresponsive) despite several weeks of intensive therapy with combined topical and systemic CS, there are the following therapeutic options:
• B-cell depletion therapy with anti-CD20 mAb (rituximab) (4.04 ± 1.74);
• For B-cell depletion therapy with anti-CD20 monoclonal antibody (mAb) using rituximab, it is recommended to apply either the rheumatoid arthritis protocol (two 1 g intravenous infusions, 2 weeks apart) or the lymphoma protocol (375 mg/m2 intravenous infusion, once weekly for 4 weeks) (4.66 ± 0.70).
• Omalizumab (4.31 ± 0.89);
• Dupilumab (4.30 ± 0.86);
• Intravenous immunoglobulins (4.57 ± 0.59);
• Immunoadsorption (4.23 ± 1.13).